RO 6958948
Alternative Names: 18F-labelled RO 6958948; [18F]6958948; [18F]RO 6958948; [18F]RO-948; F18-RO6958948; RO6958948Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Roche
- Class Imaging agents; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Cerebral haemorrhage; Subarachnoid haemorrhage; Traumatic brain injuries
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis, In the elderly, In adults) in USA (IV, Injection)
- 16 Jul 2023 Pharmacodynamics data from a phase II Swedish BioFINDER-2 trial in Alzheimer's disease (AD) presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
- 16 Jul 2023 Efficacy data from a phase II Swedish BioFINDER-2 trial in Alzheimer's disease (AD) presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)